Cardiovascular Therapy Articles & Analysis
18 news found
This progress highlights the potential for gene therapy to go beyond rare diseases and to address larger patient populations with significant unmet needs, such as chronic cardiovascular diseases. ...
BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies. February is set as American Heart Month since heart disease is the number one cause of death for most groups, affecting all ages, genders, and races. ...
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results in the second half of this ...
Mitochondrial DNA (mtDNA) plays an important role in the pathogenesis of the cardiovascular disease (CVD), especially in heart failure and ischemic heart disease. ...
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study – Preliminary efficacy data highlight XC001 potential for patients with refractory angina with no other treatment options – Treatment strategy is to use local ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announces the designation of a new reimbursement code for the CardiAMP® Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. ...
” About the CardiAMP Cell Therapy Program CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter ...
(Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. ...
Brian Davis named Chief Financial Officer XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that it has entered into a long-term lease for a new facility in Sunnyvale, California. ...
[Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina. ...
The simulation is intended to boost physician confidence, reduce operating times, and decrease the risk of complications. Cardiovascular transcatheter therapies have transformed the treatment landscape, expanding options for patients with structural heart disease. ...
ByBIOMODEX
V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial Officer (CFO) today. ...
Designed to treat patients by electrically activating the baroreflex, the body's natural mechanism to regulate cardiovascular function, BAROSTIM NEO uses CVRx-patented technology to send electrical pulses to baroreceptors located in the wall of the carotid artery, to deliver BAROSTIM THERAPY™. ...
ByCVRx
Vygon specializes in the development and commercialization of medical devices that are used by healthcare professionals in multiple clinical areas, in particular intravascular therapies, anesthesia and emergency care, as well as cardiology and vascular surgery. Oncomfort has created its digital therapy to reduce pain and anxiety for patients in these clinical ...
Ken Plunkitt, the patient’s referring physician and co-surgeon said, “We are extremely excited to offer this most promising therapy to the patients of southwest Florida. Our first patient is responding well to BAROSTIM THERAPY and is extremely happy with the process and results.” About BAROSTIM NEO BAROSTIM NEO uses CVRx-patented technology, ...
ByCVRx
” “CVRx is a pioneer in the field of neuromodulation for cardiovascular diseases. The CVRx team has developed a unique therapy with strong clinical evidence, and we are excited to support the launch of BAROSTIM NEO in the US and beyond,” added Kirk Nielsen, General Partner from Vensana Capital. ...
ByCVRx
Despite improvements in dialysis therapy, cardiovascular disease remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of that for the general population. ...